Novel patterns of gene expression in pituitary adenomas identified by complementary deoxyribonucleic acid microarrays and quantitative reverse transcription-polymerase chain reaction.
暂无分享,去创建一个
D. Brat | A. Young | N. Oyesiku | J. Parks | D J Brat | A. Neish | C O Evans | A N Young | M R Brown | J S Parks | A S Neish | N M Oyesiku | Milton R. Brown | C. Evans | M. Brown | Nelson Oyesiku | M. Brown | Milton R. Brown | N. Oyesiku | Daniel J. Brat | Andrew N. Young | Milton R. Brown | John S. Parks | Nelson M. Oyesiku
[1] K. Mimori,et al. Analysis of ornithine decarboxylase messenger ribonucleic acid expression in colorectal carcinoma , 1997, Diseases of the colon and rectum.
[2] M. Makuuchi,et al. Increased expression of ornithine decarboxylase messenger RNA in human esophageal carcinoma. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[3] S. Fukushima,et al. Inhibitory effects of 1,3-diaminopropane, an ornithine decarboxylase inhibitor, on rat two-stage urinary bladder carcinogenesis initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine. , 2000, Carcinogenesis.
[4] I. Vegh,et al. Ornithine decarboxylase activity, prolactin blood levels, and estradiol and progesterone receptors in human breast cancer , 1987, Cancer.
[5] A. Lima,et al. Biochemical parameters in the anterior pituitary during the course of tumorigenesis induced by diethylstilbestrol treatment , 1994, The Journal of Steroid Biochemistry and Molecular Biology.
[6] J. Díaz,et al. Prognostic value of ornithine decarboxylase and polyamines in human breast cancer: correlation with clinicopathologic parameters. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[7] R. J. Lee,et al. Targeted drug delivery via the folate receptor. , 2000, Advanced drug delivery reviews.
[8] N. Oyesiku,et al. Screening for MEN1 tumor suppressor gene mutations in sporadic pituitary tumors , 2000, Journal of endocrinological investigation.
[9] R. Fahlbusch,et al. Expression of menin gene mRNA in pituitary tumours. , 1999, European journal of endocrinology.
[10] W. Paschen,et al. Polyamine Metabolism in Experimental Brain Tumors of Rat , 1993, Journal of neurochemistry.
[11] C. Lavalle,et al. Prolactin, immunoregulation, and autoimmune diseases. , 1991, Seminars in arthritis and rheumatism.
[12] W. Mendelson,et al. Effect of exertion on the stimulation of ornithine decarboxylase activity by growth hormone in rats. , 1989, Life sciences.
[13] A. Antony,et al. The biological chemistry of folate receptors. , 1992, Blood.
[14] W. Nicholson,et al. Hormonal regulation of renal ornithine decarboxylase activity in the rat. , 1976, Endocrinology.
[15] L. Penland,et al. Use of a cDNA microarray to analyse gene expression patterns in human cancer , 1996, Nature Genetics.
[16] E C Wiener,et al. Targeting dendrimer-chelates to tumors and tumor cells expressing the high-affinity folate receptor. , 1997, Investigative radiology.
[17] L. Shantz,et al. Ornithine decarboxylase as a target for chemoprevention , 1995, Journal of cellular biochemistry. Supplement.
[18] H. Moch,et al. High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. , 1999, The American journal of pathology.
[19] H. Snodgrass,et al. Cloning and Mrna Expression Analysis of a Novel Human Protooncogene, C-merr , 2022 .
[20] J. J. Mukherjee,et al. The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors. , 1998, The Journal of clinical endocrinology and metabolism.
[21] H. Hanafusa,et al. Biological Effects of c-Mer Receptor Tyrosine Kinase in Hematopoietic Cells Depend on the Grb2 Binding Site in the Receptor and Activation of NF-κB , 1999, Molecular and Cellular Biology.
[22] P. Elwood,et al. The influence of extracellular folate concentration on methotrexate uptake by human KB cells. Partial characterization of a membrane-associated methotrexate binding protein. , 1986, The Journal of biological chemistry.
[23] Brennan,et al. Association between high levels of ornithine decarboxylase activity and favorable prognosis in human colorectal carcinoma. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[24] L. Hood,et al. Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray. , 1999, Gene.
[25] S. Melmed,et al. Pituitary Tumor Pathogenesis1 , 1997 .
[26] G. Vailati,et al. Polyamines: current review and their perspectives in neurosurgery. , 1982, Journal of neurosurgical sciences.
[27] S. Melmed,et al. Genetic basis of endocrine disease: pituitary tumor pathogenesis. , 1997, The Journal of clinical endocrinology and metabolism.
[28] K. Kovacs,et al. Clonal origin of pituitary adenomas. , 1990, The Journal of clinical endocrinology and metabolism.
[29] J. Dussault,et al. Thyroid hormones modulate ornithine decarboxylase in the immature rat cerebellum. , 1984, Canadian journal of physiology and pharmacology.
[30] S. Melmed,et al. Diagnosis and management of nonfunctioning pituitary tumors. , 1996, Annual review of medicine.
[31] A. Pegg,et al. Polyamine metabolism and its importance in neoplastic growth and a target for chemotherapy. , 1988, Cancer research.
[32] W. Gunning,et al. Expression of folate receptor type alpha in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[33] A. Arnold,et al. Clinically nonfunctioning pituitary tumors are monoclonal in origin. , 1990, The Journal of clinical investigation.
[34] C. J. Mathias,et al. A kit formulation for preparation of [(111)In]In-DTPA-folate, a folate-receptor-targeted radiopharmaceutical. , 1998, Nuclear medicine and biology.
[35] P. Low,et al. Indium-111-DTPA-folate as a potential folate-receptor-targeted radiopharmaceutical. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[36] N. Seiler,et al. Polyamine metabolism as target for cancer chemoprevention (review). , 1998, International journal of oncology.
[37] P. Low,et al. Synthesis of [(99m)Tc]DTPA-folate and its evaluation as a folate-receptor-targeted radiopharmaceutical. , 2000, Bioconjugate chemistry.
[38] G. P. Beardsley,et al. 5,10-Dideazatetrahydrofolic acid (DDATHF) transport in CCRF-CEM and MA104 cell lines. , 1993, The Journal of biological chemistry.
[39] N. Oyesiku,et al. Pituitary Adenomas: Screening for Gαq Mutations , 1997 .
[40] J. Moulinoux,et al. Benefits of complete polyamine deprivation in hormone responsive and hormone resistant MCF-7 human breast adenocarcinoma in vivo. , 2000, Anticancer research.
[41] Bettuzzi Saverio,et al. Tumor progression is accompanied by significant changes in the levels of expression of polyamine metabolism regulatory genes and clusterin (sulfated glycoprotein 2) in human prostate cancer specimens. , 2000 .
[42] J. Holm,et al. High-affinity folate receptor in human ovary, serous ovarian adenocarcinoma, and ascites: radioligand binding mechanism, molecular size, ionic properties, hydrophobic domain, and immunoreactivity. , 1999, Archives of biochemistry and biophysics.
[43] S. Asa,et al. The MEN-1 gene is rarely down-regulated in pituitary adenomas. , 1998, The Journal of clinical endocrinology and metabolism.
[44] V. Zurawski,et al. Cellular localization of the folate receptor: potential role in drug toxicity and folate homeostasis. , 1992, Cancer research.
[45] R. Thakker,et al. Sequence analysis and transcript expression of the MEN1 gene in sporadic pituitary tumours , 1999, British Journal of Cancer.
[46] B. Schimmer,et al. Regulation of ornithine decarboxylase activity by corticotropin in adrenocortical tumor cell clones: roles of cyclic AMP and cyclic AMP-dependent protein kinase. , 1980, Proceedings of the National Academy of Sciences of the United States of America.
[47] M. Mark,et al. Characterization of Gas6, a Member of the Superfamily of G Domain-containing Proteins, as a Ligand for Rse and Axl (*) , 1996, The Journal of Biological Chemistry.
[48] P. Low,et al. Receptor-mediated targeting of 67Ga-deferoxamine-folate to folate-receptor-positive human KB tumor xenografts. , 1999, Nuclear medicine and biology.
[49] Ronald W. Davis,et al. Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray , 1995, Science.
[50] U. Bachrach,et al. Polyamines induce malignant transformation in cultured NIH 3T3 fibroblasts. , 1998, The international journal of biochemistry & cell biology.
[51] L. Marton,et al. Polyamines as targets for therapeutic intervention. , 1995, Annual review of pharmacology and toxicology.
[52] J. Ragoussis,et al. Genomic organization of the human folate receptor genes on chromosome 11q13. , 1992, Genomics.
[53] W. Nicholson,et al. Stimulation of adrenal ornithine decarboxylase by adrenocorticotropin and growth hormone. , 1973, Endocrinology.
[54] Cheryl Schmidt,et al. Identification of genes differentially over-expressed in lung squamous cell carcinoma using combination of cDNA subtraction and microarray analysis , 2000, Oncogene.
[55] C. Schneider,et al. The protein encoded by a growth arrest-specific gene (gas6) is a new member of the vitamin K-dependent proteins related to protein S, a negative coregulator in the blood coagulation cascade , 1993, Molecular and cellular biology.
[56] S. Bettuzzi,et al. Tumor progression is accompanied by significant changes in the levels of expression of polyamine metabolism regulatory genes and clusterin (sulfated glycoprotein 2) in human prostate cancer specimens. , 2000, Cancer research.
[57] S. Asa,et al. The cytogenesis and pathogenesis of pituitary adenomas. , 1998, Endocrine reviews.